PARSIPPANY, NJ, Aug 10, 2009 (MARKETWIRE via COMTEX) -- The Medicines Company (NASDAQ: MDCO) announced today that it had
responded to inaccurate implications in a column in The New York
Times on August 9, 2009 by Frank Rich and a report that aired on
Rachel Maddow's news show on MSNBC on August 6, 2009. The column and
report both contained statements that incorrectly created the
impression that The Medicines Company has engaged lobbyists to oppose
pending healthcare reform legislation and supported efforts to
disrupt debate about health care reform. Neither implication is
accurate. The Medicines Company has not opposed any of the pending
health care reform bills, and has not in any way supported any
efforts to disrupt open debate about health care reform. The
company's lobbying efforts relate solely to a change in the U.S.
patent laws to enable more research, innovation and cost saving in
health care. The Medicines Company sincerely hopes that The New York
Times and MSNBC, both respected news outlets, will correct their
stories.
About The Medicines Company
The Medicines Company (NASDAQ: MDCO) is focused on advancing the
treatment of critical care patients through the delivery of
innovative, cost-effective medicines to the worldwide hospital
marketplace. The Company markets Angiomax(R) (bivalirudin) in the
United States and other countries for use in patients undergoing
coronary angioplasty, and Cleviprex(R) (clevidipine butyrate)
injectable emulsion in the United States for the reduction of blood
pressure when oral therapy is not feasible or not desirable. The
Company also has two products in late stage development, cangrelor,
an investigational antiplatelet agent and oritavancin, a
semi-synthetic lipoglycopeptide antibiotic currently awaiting EU
regulatory approval. The Company's pipeline also includes a serine
protease inhibitor, CU2010, in early-stage development. The Medicines
Company's website is www.themedicinescompany.com.
Cautionary Note Regarding Forward-Looking Statements
Statements contained in this press release about The Medicines
Company that are not purely historical, and all other statements that
are not purely historical, may be deemed to be forward-looking
statements for purposes of the safe harbor provisions under The
Private Securities Litigation Reform Act of 1995. Without limiting
the foregoing, the words "believes," "anticipates," "expects" and
"estimates" and similar expressions are intended to identify
forward-looking statements. These forward-looking statements involve
known and unknown risks and uncertainties that may cause the
Company's actual results, levels of activity, performance or
achievements to be materially different from those expressed or
implied by these forward-looking statements. Important factors that
may cause or contribute to such differences include: whether the
Company will be able to obtain regulatory approvals; whether the
Company's products and product candidates will advance in the
clinical trial process on a timely basis or at all; whether clinical
trial results will warrant submission of applications for regulatory
approval; whether physicians, patients and other key decision-makers
will accept clinical trial results; whether the Company will be able
to successfully distribute and market its approved products; and such
other factors as are set forth in the risk factors detailed from time
to time in the Company's periodic reports and registration statements
filed with the Securities and Exchange Commission including, without
limitation, the risk factors detailed in the Company's Annual Report
on Form 10-Q filed on May 11, 2009, which are incorporated herein by
reference. The Company specifically disclaims any obligation to
update these forward-looking statements.
Contact:
Paul Antinori
The Medicines Company
Phone: (973) 290-6000
investor.relations@themedco.com
SOURCE: The Medicines Company
mailto:investor.relations@themedco.com
